A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

Summary

The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are: What is the safe dose of KQB368 as a monotherapy? Does KQB368 decrease the size of the tumor? What happens to KQB368 in the body? Participants will: Take KQB368 orally daily in 21-day cycles Return to the study site about 7 times in the first 5 weeks, and then once at the beginning of every 21-day cycle after that

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Solid Tumors
• Colorectal Cancer (CRC)
• Non-Small Cell Lung Cancer
• Uterine Cancer
• KRAS G12C Mutations
• KRAS G12S Mutations

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Kumquat Biosciences Inc.

Last updated on ClinicalTrials.gov

November 3, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites